Overactive Bladder Treatment Market Challenges, Forecast and Strategies To 2023

Posted by Vinit on January 14th, 2021

The growing prevalence of Overactive Bladder (OAB) with the growing geriatric population and rising occurrences of neurological diseases are major factors driving the growth of the market. Additionally, according to the Advanced Urology Institutes in 2015, 1/3rd of men and women between the ages of 30 to70, had lost bladder control.  Moreover, the growing development of innovative intravesical therapies and increasing commercialization activities by pharma companies are expected to propel the market growth.

Regional Analysis

The global overactive bladder treatment market consists of four regions, namely, the Americas, Europe, Asia-Pacific, and the Middle East and Africa. North America is expected to dominate the market in the Americas owing to the increasing geriatric population, growing incidences of OAB and urinary incontinence symptoms, and the availability of healthcare coverage systems such as Medicare.

On the other hand, lack of awareness in the developing countries and undesired systemic effects of some current treatment options may hamper the growth of the market during the forecast period.

Global Overactive Bladder Treatment Key Players

Some of the prominent players in the market are Astellas Pharma Inc., Pfizer, Inc., Teva Pharmaceutical Industries Ltd., Allergan, Plc., Mylan N.V., Endo International Plc, Hisamitsu Pharmaceutical Co., Inc., Sanofi S. A., Aurobindo Pharma Limited, Johnson & Johnson, Intas Pharmaceuticals Ltd., Apotex Inc., Macleods Pharmaceuticals Ltd., Medtronic PLC, Cogentix Medical, Inc., and others.

Europe is expected to hold the second position in the market owing to the increasing healthcare expenditure, growing occurrences of OAB, and the availability of reimbursement options. Asia-Pacific is anticipated to be the fastest-growing market owing to the growing prevalence of OAB, rising geriatric population, and growing awareness about overactive bladder condition. Furthermore, the Middle East and Africa are likely to hold the least share in the global overactive bladder treatment market.